| First Author | Redmond WL | Year | 2023 |
| Journal | Front Immunol | Volume | 14 |
| Pages | 1057702 | PubMed ID | 36911733 |
| Mgi Jnum | J:334063 | Mgi Id | MGI:7445354 |
| Doi | 10.3389/fimmu.2023.1057702 | Citation | Redmond WL, et al. (2023) Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA. Front Immunol 14:1057702 |
| abstractText | Cancer immunotherapy such as anti-PD-1/anti-PD-L1 immune checkpoint blockade (ICB) can provide significant clinical benefit in patients with advanced malignancies. However, most patients eventually develop progressive disease, thus necessitating additional therapeutic options. We have developed a novel agent, a-TEA-LS, that selectively induces tumor cell death while sparing healthy tissues, leading to increased activation of tumor-reactive T cells and tumor regression. In the current study, we explored the impact of combined a-TEA-LS + ICB in orthotopic and spontaneously arising murine models of mammary carcinoma. We found that a-TEA-LS + ICB led to increased production of pro-inflammatory cytokines that were associated with a reduction in tumor growth and prolonged survival. Together, these data demonstrate the potential utility of a-TEA-LS + ICB for the treatment of breast cancer and provide the rationale for clinical translation of this novel approach. |
